Profil
Sharon Longhurst is currently an Independent Director at Idogen AB and Elicera Therapeutics AB. Previously, she worked as the Head-Chemistry, Manufacturing & Control at Mendus AB and as the Vice President-Development at Gadeta BV from 2021 to 2023.
Dr. Longhurst holds a doctorate degree from the University of Warwick and an undergraduate degree from the University of Surrey.
Postes actifs de Sharon Longhurst
| Sociétés | Poste | Début |
|---|---|---|
| ELICERA THERAPEUTICS AB | Directeur/Membre du Conseil | 01/01/2024 |
Idogen AB
Idogen AB BiotechnologyHealth Technology Develops cell therapies for treatment of autoimmune diseases | Directeur/Membre du Conseil | 12/05/2020 |
Anciens postes connus de Sharon Longhurst
| Sociétés | Poste | Fin |
|---|---|---|
Gadeta BV
Gadeta BV BiotechnologyHealth Technology Conducts research and develops medicines & treatment methods for cancer | Corporate Officer/Principal | 01/08/2023 |
| MENDUS AB | Corporate Officer/Principal | - |
Formation de Sharon Longhurst
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
University of Warwick
University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Surrey
University of Surrey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mendus AB
Mendus AB BiotechnologyHealth Technology Develops immunotherapies for therapeutic treatment of cancer | Health Technology |
Idogen AB
Idogen AB BiotechnologyHealth Technology Develops cell therapies for treatment of autoimmune diseases | Health Technology |
Gadeta BV
Gadeta BV BiotechnologyHealth Technology Conducts research and develops medicines & treatment methods for cancer | Health Technology |
Elicera Therapeutics AB
Elicera Therapeutics AB BiotechnologyHealth Technology Develops and trades cell and gene therapies in immune-oncology | Health Technology |
















